New product: Otezla (apremilast) 30mg tablets -

New product: Otezla (apremilast) 30mg tablets
Information type: Drug prescribing
Source: Glenmark Pharmaceuticals Europe Ltd
Specialities: Skin disorders
Summary
Apremilast is licensed for the treatment of active psoriatic arthritis (in adults who have had an inadequate response or who have been intolerant to a prior DMARD therapy) and severe chronic plaque psoriasis (in adults in whom other systemic therapy has failed or is unsuitable).
UKMi comment
Apremilast is an orally active agent that inhibits multiple pro-inflammatory mediators including TNF-alpha, interleukins 6, 17 & 23, and interferon-gamma. NICE is appraising its use in both indications; final guidance is expected in August 2015.
Related links: NICE guidance on psoriatic arthritis NICE guidance on psoriasis